[HTML] sciencedirect.com

[HTML][HTML] Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

B Sangro, I Melero, S Wadhawan, RS Finn… - Journal of …, 2020 - Elsevier
Background & Aims Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable
responses, manageable safety, and increased survival in patients with advanced …
被引用次数：318 相关文章

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

B Sangro, I Melero, S Wadhawan, RS Finn… - 2020 - dadun.unav.edu
Background & Aims: Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable
responses, manageable safety, and increased survival in patients with advanced …
[HTML] nih.gov

[HTML][HTML] Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

B Sangro, I Melero, S Wadhawan, RS Finn… - Journal of …, 2020 - ncbi.nlm.nih.gov
Methods: Fresh and archival tumour samples from dose-escalation and dose-expansion
phases of the CheckMate 040 trial were analysed by immunohistochemistry and RNA …

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.

B Sangro, I Melero, S Wadhawan, RS Finn… - Journal of …, 2020 - europepmc.org
Methods Fresh and archival tumour samples from dose-escalation and dose-expansion
phases of the CheckMate 040 trial were analysed by immunohistochemistry and RNA …

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

B Sangro, I Melero, S Wadhawan… - Journal of …, 2020 - journal-of-hepatology.eu
Background & Aims Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable
responses, manageable safety, and increased survival in patients with advanced …

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

B Sangro, I Melero, S Wadhawan… - Journal of …, 2020 - pubmed.ncbi.nlm.nih.gov
Background & aims Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable
responses, manageable safety, and increased survival in patients with advanced …

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

B Sangro, I Melero, S Wadhawan, RS Finn… - 2020 - lareferencia.info
Background & Aims: Nivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable
responses, manageable safety, and increased survival in patients with advanced …

[引用][C] Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

B Sangro, I Melero, S Wadhawan, RS Finn… - Journal of …, 2020 - cir.nii.ac.jp
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients
with advanced hepatocellular carcinoma | CiNii Research CiNii 国立情報学研究所 学術情報 …

Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.

B Sangro, I Melero, S Wadhawan, RS Finn… - Journal of …, 2020 - europepmc.org
Methods Fresh and archival tumour samples from dose-escalation and dose-expansion
phases of the CheckMate 040 trial were analysed by immunohistochemistry and RNA …